Followers | 177 |
Posts | 24543 |
Boards Moderated | 13 |
Alias Born | 04/03/2002 |
Tuesday, November 01, 2016 10:55:58 AM
Video Link: http://ceolive.tv/in-depth-interview-with-ceo-of-ground-breaking-life-sciences-company/
Ground Breaking Life Sciences Company Pursues $6 Billion Market
In this episode of CEOLIVE.TV we have an in-depth conversation with Mr. Richard Schumacher, CEO of Pressure BioScience (PBIO).
Pressure Bio develops, markets and sells proprietary lab instruments and consumables to the $6 billion life science sample prep market.
Their patented PCT platform has been installed in over 250 PCT systems in 160 sites worldwide.
The company’s PCT product line has grown rapidly over the past year and as a result, product revenue has jumped 8.3% and total revenue increased 34% last year.
Although it’s in the early stages of commercialization the company’s PCT platform holds competitive advantages over incumbent technologies in many important aspects related to sample preparation.
A report from Zach’s Small Cap Research Analyst, Grant Zeng, stated that PBIO’s shares are deeply undervalued and based on current fundamentals gave a conservative price target of $2.50 per share.
Pressure Bio was also recently featured in an article on SECFilings.com, “How to Invest in the Cancer Moonshot” which you can read here: http://bit.ly/2f5JbDA
Company Overview
Pressure BioSciences, Inc. (OTCQB:PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. The Company’s products are based on the unique properties of both constant and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. The Company’s primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use their products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
Valuation
PBIO’s Pressure Cycling Technology platform (PCT) is patented and uses alternate cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely and conveniently control the rupture (lysis) of cells and tissues from human, animal, plant and microbial sources. The Company has sold 300 instrument systems worldwide to leading academic, government, biotech and pharma laboratories. Additionally, there have been over 100 journal articles and peer reviewed publications on the advantages of PCT technology. Following a recent $6.3 million capital raise, a recent co-marketing deal with SCIEX (leader in mass spectrometry (MS)), and an expansion of the Company’s sales and marketing team, sales should begin to show strong increases going forward.
PBIO CEO Richard T. Schumacher is a serial entrepreneur who has had substantial success in growing and operating Biotech and Pharma businesses in the past; as President and Co-founder of Panacos Pharma, he helped to significantly improve the Company from a struggling start-up to a $700 million market cap in five years. Relative to sales potential, if PBIO can capture only 25% of the market opportunity in MS, it could lead to $75 million in device sales and $36 million in annual, recurring revenue. Additional long-term opportunities for PCT also exist.
Recent PBIO News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/27/2024 06:42:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 10:30:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:24:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:44:21 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 08:18:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/25/2023 09:10:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:19:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:17:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:14:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:12:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:08:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/24/2023 02:03:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:26:41 PM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM